Bullboard - Stock Discussion Forum Valeo Pharma Inc VPHIF

Healthcare

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler,... see more

Add To Watchlist

GREY:VPHIF - Post Discussion

Valeo Pharma Inc > VPH: Announces higher revenue guidance for Q4/2022.

View:

Post by Royal10 on Nov 15, 2022 1:34pm

VPH: Announces higher revenue guidance for Q4/2022.

VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE

Valeo Pharma Inc. has raised revenue guidance for its fourth quarter of 2022 to $12.5-million to $13-million, an increase of 14 per cent to 18 per cent over previously issued guidance of $11-million. The company is also increasing its fiscal 2022 revenue guidance to $27.5-million to $28-million, a forecasted increase exceeding 100 per cent compared with fiscal 2021 revenues of $13.6-million.

VPH is trading at only 67 cents per share.
Fidelity bought 1,860,000 shares since July 4/2022.

347